Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Table 1 Incidence of TD in the PD- 1/PD-L1 inhibitor and non-PD- 1/PD-L1 inhibitor groups

From: Thyroid dysfunction as a predictor of PD- 1/PD-L1 inhibitor efficacy in advanced lung cancer

 

PD- 1/PD-L1 inhibitor group

Non-PD- 1/PD-L1 inhibitor group

p

 

(n = 60)

(n = 60)

Occurrence of TD (n (%))

29 (48.3%)

10 (16.7%)

< 0.001

Time of TD occurrence (M, IQR)

4.13 (6.04) months

1.79 (2.44) months

0.079

Types of TD (n (%))

 Subclinical hypothyroidism

12 (41.4%)

6 (60.0%)

0.156

 Hypothyroidism

8 (27.6%)

1 (10.0%)

 Subclinical hyperthyroidism

2 (6.9%)

1 (10.0%)

 Hyperthyroidism

6 (20.7%)

0 (0.0%)

 Low T3 syndrome

1 (3.4%)

2 (20.0%)

Severity of TD (n (%))

 Grade 1

24 (82.8%)

10 (100.0%)

0.302

 Grade 2

5 (17.2%)

0 (0.0%)

  1. The occurrence of TD is defined as the time interval from the start of the treatment to the first observation of TD. The severity of TD was recorded as the highest grade rating throughout the course of treatment
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us